Palivizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1498 publications

Construction and verification of infectious clones for human respiratory syncytial virus subgroup A genotype ON1 expressing fluorescent reporter genes

Construction and verification of infectious clones for human respiratory syncytial virus subgroup A genotype ON1 expressing fluorescent reporter genes

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: June 22, 2026

Phylodynamics and molecular epidemiology of the respiratory syncytial virus fusion protein in China.

Phylodynamics and molecular epidemiology of the respiratory syncytial virus fusion protein in China.

Journal: Microbiology spectrum

Published: May 01, 2026

Early-Life Viral Lower Respiratory Tract Infections and Their Impact on Childhood Asthma: Molecular Endotypes and Prevention Strategies.

Early-Life Viral Lower Respiratory Tract Infections and Their Impact on Childhood Asthma: Molecular Endotypes and Prevention Strategies.

Journal: Pediatric allergy, immunology, and pulmonology

Published: April 28, 2026

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

Journal: JAMA network open

Published: April 10, 2026

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Journal: Human vaccines & immunotherapeutics

Published: April 01, 2026

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States.

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States.

Journal: Vaccines

Published: March 31, 2026

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab: A FAERS Observational Study.

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab: A FAERS Observational Study.

Journal: Kansas journal of medicine

Published: March 23, 2026

Prevention of respiratory syncytial virus in children

Prevention of respiratory syncytial virus in children

Journal: Ugeskrift for laeger

Published: February 25, 2026

Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS).

Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS).

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: February 24, 2026

Respiratory Syncytial Virus Infection Triggering a Pulmonary Hypertensive Crisis in a Boy With Prader-Willi Syndrome-Associated Sleep-Disordered Breathing.

Respiratory Syncytial Virus Infection Triggering a Pulmonary Hypertensive Crisis in a Boy With Prader-Willi Syndrome-Associated Sleep-Disordered Breathing.

Journal: Cureus

Published: February 19, 2026

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.

Journal: Children (Basel, Switzerland)

Published: February 04, 2026

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025.

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025.

Journal: EClinicalMedicine

Published: January 25, 2026

Showing 1-12 of 1,498

Last Updated: 06/30/2026